2-ACETYLNAPHTHO[2,3-B]FURAN -4,9-DIONE FOR USE ON TREATING CANCER
申请人:BOSTON BIOMEDICAL, INC.
公开号:US20160030384A1
公开(公告)日:2016-02-04
The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
Semisynthesis and antitumoral activity of 2-acetylfuranonaphthoquinone and other naphthoquinone derivatives from lapachol
作者:Kenneth O. Eyong、Ponminor S. Kumar、Victor Kuete、Gabriel N. Folefoc、Ephriam A. Nkengfack、Sundarababu Baskaran
DOI:10.1016/j.bmcl.2008.09.053
日期:2008.10
Ozonolysis of lapachol (1), resulting in an unusual formation of a potent antitumor agent 2-acetylfuranonaphthoquinone (3) along with the expected aldehyde 6, is described. The reaction of lapachol (1) with CAN in dry acetonitrile leading to biologically active furanonaphthoquinones is also reported. The antitumoral activity of the tested compounds on human DU-145 prostate carcinoma cells was evaluated following XTT assay. The results revealed that 2-(1-methylethenyl)-2,3-dihydronaphtho[2,3-b]furan-4,9-dione (5), beta-lapachone (10) and dehydro-beta-lapachone diacetate (11) showed 100% inhibition at 25 mu g/ml. All the tested samples showed dose-dependent activity. (C) 2008 Elsevier Ltd. All rights reserved.
NOVEL COMPOUNDS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS
申请人:1Globe Biomedical Co., Ltd.
公开号:EP3108750B1
公开(公告)日:2018-07-04
METHODS FOR TREATING CANCER
申请人:BOSTON BIOMEDICAL, INC.
公开号:US20180085341A1
公开(公告)日:2018-03-29
Methods comprising administering and kits comprising at least one paclitaxel compound and at least one compound of formula (I).
COMPOSITIONS COMPRISING A CANCER STEMNESS INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT FOR USE IN TREATING CANCER
申请人:Boston Biomedical, Inc.
公开号:US20180140572A1
公开(公告)日:2018-05-24
Disclosed herein are methods for use in treating cancer comprising administering at least one cancer sternness inhibitor, for example, at least one STAT3 pathway inhibitor such as 2-acetylnaphtho [2, 3-b] furan-4, 9-dione, in order to sensitize or re-sensitive a cancer that is naive, resistant, or/and refractory to at least one immunotherapeutic agent, such as at least one immune checkpoint modulator.